Skin tumors induced by sorafenib; paradoxic RAS-RAF pathway activation and oncogenic mutations of HRAS, TP53, and TGFBR1.
Arnault JP, Mateus C, Escudier B, Tomasic G, Wechsler J, Hollville E, Soria JC, Malka D, Sarasin A, Larcher M, André J, Kamsu-Kom N, Boussemart L, Lacroix L, Spatz A, Eggermont AM, Druillennec S, Vagner S, Eychène A, Dumaz N, Robert C.
Arnault JP, et al. Among authors: soria jc.
Clin Cancer Res. 2012 Jan 1;18(1):263-72. doi: 10.1158/1078-0432.CCR-11-1344. Epub 2011 Nov 17.
Clin Cancer Res. 2012.
PMID: 22096025